Pharmatech

The chart shows the growth of an initial investment of $10,000 in Pharmatech, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Quarterly

As of Nov 13, 2024, the Pharmatech returned 80.75% Year-To-Date and 46.73% of annualized return in the last 10 years.

The table below presents the monthly returns of Pharmatech, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.

Pharmatech has an expense ratio of 0.00%, indicating no management fees are charged. Below you can find the expense ratios of portfolio funds side-by-side and effortlessly compare their relative costs.

The current risk-adjusted rank of Pharmatech is 87, placing it in the top 13% of portfolios on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Pharmatech provided a 0.52% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pharmatech. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pharmatech was 27.81%, occurring on Mar 23, 2020. Recovery took 33 trading sessions.

The current Pharmatech drawdown is 0.32%.

The current Pharmatech volatility is 6.02%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.